SPSB1 Knockout cell line (THP-1)

CRISPR knockout cell lines are engineered through targeted genome editing to eliminate gene function, supporting studies of cellular biology, disease mechanisms, and drug discovery.

THP-1 is a human monocytic leukemia cell line established from the peripheral blood of a 1-year-old male patient with acute monocytic leukemia at relapse. The cells exhibit monocytic characteristics, including expression of Fc and complement receptors, lysozyme production, esterase activity, and phagocytic capacity. THP-1 cells can be differentiated into macrophage-like cells under appropriate stimulation and are widely used as a model for studying monocyte/macrophage biology, immune responses, inflammation, differentiation, and host–pathogen interactions.

Comprehensive quality control includes STR authentication, sterility testing (bacteria and fungi), and mycoplasma screening to ensure purity and performance. Genotype is confirmed by two rounds of PCR and Sanger sequencing, and complete validation reports are provided for make-to-order products.